Synklino
Synklino is a clinical-stage biotechnology company developing SYN002, a therapy designed to eliminate cytomegalovirus (CMV) in transplant recipients. The company focuses on treating donor organs ex vivo prior to transplantation or treating recipients in vivo to prevent viral reactivation. Its primary target market is kidney transplant patients who are at risk of CMV-related morbidity and mortality.
Healthtech
Biotechnology
Biotech
Pharmaceuticals
Funding summary
- Total raised
- €29.8M
- Funding rounds
- 2
Investors in Synklino
Investors on record for Synklino. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Synklino?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors